The cancer diagnostics company BiBBInstruments AB announced on Tuesday the successful use of EndoDrill GI during a live broadcasted biopsy procedure at Hospital Pedro Hispano in Porto, Portugal.
The procedure, which involved sampling a pancreatic tumour, was conducted by Dr Francisco Baldaque Silva and broadcast during the Portuguese Society of Gastrointestinal Endoscopy's annual event, Live Sped 2025.
EndoDrill GI, the world's first CE-marked electric-driven biopsy instrument for endoscopy, was tested in real-time, demonstrating its capabilities. The procedure received positive feedback from both the team and the audience, with praise for the high-quality core biopsies.
Dr Baldaque Silva suggested the live biopsy after using EndoDrill GI at both Karolinska University Hospital and Hospital Pedro Hispano. EndoDrill GI is used for EUS-guided tissue sampling across various gastrointestinal indications, including the pancreas, stomach and liver. The successful demonstration marks a significant milestone for BiBBInstruments AB's product.
Oncoinvent reports positive 18-month Phase 1 data for Radspherin in ovarian cancer trial
argenx receives positive CHMP opinion for VYVGART subcutaneous injection in CIDP treatment
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Johnson & Johnson reports TAR-200 monotherapy study data in bladder cancer
InnoCare receives NMPA approval for orelabrutinib as first-line treatment for CLL/SLL in China
RaySearch Laboratories announces order from Odense University Hospital for RayStation
Primo Biotechnology's Taoyuan facility granted PIC/S GMP Certification
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment
Guardant Health and Pfizer enter global collaboration to advance cancer therapy development
Adcendo to present clinical stage ADC data at 2025 AACR Annual Meeting
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)